share_log

藥明生物：截至2024年5月31日止股份發行人的證券變動月報表

WUXI BIO: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2024

Hong Kong Stock Exchange ·  Jun 6 19:38
Summary by Futu AI
藥明生物（WuXi Biologics (Cayman) Inc.）於2024年6月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年5月31日的公司股份變動情況。報告顯示，公司的法定/註冊股本結存維持不變，為6,000,000,000股普通股，每股面值為USD1/120,000，總額為50,000美元。此外，報告中提到，於2024年5月期間，因行使股份期權而新增的股份總數為2,164,660股，並獲得資金總額為487,771.02美元。同時，公司於2024年5月進行了股份回購，但該等股份於報告截止日期尚未註銷。藥明生物確認，所有發行的證券均已獲得董事會的正式授權和批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
藥明生物（WuXi Biologics (Cayman) Inc.）於2024年6月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年5月31日的公司股份變動情況。報告顯示，公司的法定/註冊股本結存維持不變，為6,000,000,000股普通股，每股面值為USD1/120,000，總額為50,000美元。此外，報告中提到，於2024年5月期間，因行使股份期權而新增的股份總數為2,164,660股，並獲得資金總額為487,771.02美元。同時，公司於2024年5月進行了股份回購，但該等股份於報告截止日期尚未註銷。藥明生物確認，所有發行的證券均已獲得董事會的正式授權和批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
On June 6, 2024, WuXi Biologics (Cayman) Inc. submitted the latest monthly report of securities changes to Hong Kong Exchanges and Clearing Limited, reporting on the company's share changes as of May 31, 2024. The report showed that the company's statutory/registered share capital remained unchanged at 6,000,000,000 ordinary shares with a par value of USD1/120,000 per share, totaling 50,000 US dollars. In addition, the report mentioned that during May 2024, 2,164,660 shares were added due to the exercise of share options, with a total funding of 487,771.02 US dollars. At the same time, the company bought back shares in May 2024, but these shares have not been cancelled as of the report deadline. WuXi Biologics confirmed that all securities issued have received formal authorization and approval from the board of directors, and comply with the relevant requirements of the Listing Rules of the Hong Kong Stock Exchange.
On June 6, 2024, WuXi Biologics (Cayman) Inc. submitted the latest monthly report of securities changes to Hong Kong Exchanges and Clearing Limited, reporting on the company's share changes as of May 31, 2024. The report showed that the company's statutory/registered share capital remained unchanged at 6,000,000,000 ordinary shares with a par value of USD1/120,000 per share, totaling 50,000 US dollars. In addition, the report mentioned that during May 2024, 2,164,660 shares were added due to the exercise of share options, with a total funding of 487,771.02 US dollars. At the same time, the company bought back shares in May 2024, but these shares have not been cancelled as of the report deadline. WuXi Biologics confirmed that all securities issued have received formal authorization and approval from the board of directors, and comply with the relevant requirements of the Listing Rules of the Hong Kong Stock Exchange.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.